CymitQuimica logo
Angiogenesi

Angiogenesi

Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.

Sottocategorie di "Angiogenesi"

Mostrare 6 più sottocategorie

Trovati 2040 prodotti di "Angiogenesi"

Ordinare per

Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
prodotti per pagina.
  • EGFR/VEGFR2-IN-5


    EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.
    Formula:C17H15N7O5S
    Colore e forma:Solid
    Peso molecolare:429.41
  • LAE-102


    LAE-102 is a monoclonal antibody that acts as an antagonist of activin receptor II-A (ACTRIIA/ACVR2). It shows potential for research in the fields of endocrine and metabolic disorders, oncology, and respiratory diseases.
    Colore e forma:Odour Liquid
  • FGFRs-IN-1


    <p>FGFRs-IN-1 (Compound A16) is an orally active inhibitor targeting FGFR1/2/3/4, with IC50 values of 2.3, 7, 11, and 163 nM respectively. It also inhibits VEGFR1/2/3, Abl, and Flt3, with IC50 values of 61, 176, 112, 26, and 353 nM. The compound shows weak inhibition of CYP enzymes. FGFRs-IN-1 reduces the expression of α-SMA and collagen I, and it inhibits epithelial-mesenchymal transition (EMT) in A549 cells stimulated by TGF-β1. Additionally, FGFRs-IN-1 demonstrates anti-inflammatory activity in mouse models of lung fibrosis induced by Bleomycin and liver fibrosis induced by CCl4.</p>
    Formula:C28H26Cl2N4O3
    Colore e forma:Solid
    Peso molecolare:537.44
  • MY-1576


    MY-1576 is a FAK inhibitor with an IC50 of 8 nM. It activates the Hippo pathway, thereby inhibiting YAP/TAZ regulation. Additionally, MY-1576 effectively suppresses tumor growth in the KYSE30 xenograft mouse model, demonstrates good safety, and efficiently downregulates FAK autophosphorylation and YAP/TAZ levels in vivo.
    Formula:C25H29ClN8O2
    Colore e forma:Solid
    Peso molecolare:509
  • OK2


    OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.
    Formula:C42H62N14O9
    Purezza:98%
    Colore e forma:Solid
    Peso molecolare:907.03
  • Cetuximab (PBS)


    Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.
    Colore e forma:Odour Liquid
  • Scr-IN-1


    Scr-IN-1 (Compound 4e) is a tyrosine kinase inhibitor demonstrating inhibitory activity against HCT-116 and MIA-PaCa-2 cells, with IC50 values of 0.16 μM and 1.16 μM, respectively. It shows selectivity towards HCT-116 cells and MIA-PaCa-2 cells, with a selectivity index (SI) greater than 625 and 86. Scr-IN-1 induces apoptosis in HCT-116 colon cancer cells without altering the proportion of necrotic cells and is a potential novel SRC kinase inhibitor for HCT-116 cells. This compound is suitable for cancer research.
    Formula:C26H16ClF3N2O3
    Colore e forma:Solid
    Peso molecolare:496.87
  • MS9427

    CAS:
    <p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>
    Formula:C48H58ClFN8O12
    Colore e forma:Solid
    Peso molecolare:993.47
  • EGFR-IN-162


    <p>EGFR-IN-162 (compound 20) is an effective EGFR inhibitor that enhances both early and late apoptosis (EGFR) as well as necrosis (necrosis). It shows potential for use in breast cancer research.</p>
    Formula:C27H31N3O2
    Colore e forma:Solid
    Peso molecolare:429.24163
  • SNIPER(ABL)-047


    SNIPER(ABL)-047, a compound that links HG-7-85-01 (an ABL inhibitor) to MV-1 (an IAP ligand) via a linker, effectively decreases the BCR-ABL protein levels,
    Formula:C67H82F3N11O9S
    Purezza:98%
    Colore e forma:Solid
    Peso molecolare:1274.5
  • DD0-2363


    <p>DD0-2363 (Compound 32d) is a dual-target inhibitor of WDR5-MLL1/HDAC. It can suppress the proliferation of acute myeloid leukemia cells and induce apoptosis. With its antitumor properties, DD0-2363 is applicable for research on acute myeloid leukemia.</p>
    Formula:C36H36ClFN6O4
    Colore e forma:Solid
    Peso molecolare:671.16
  • EGFR/BRAFV600E-IN-4


    <p>EGFR/BRAFV600E-IN-4 (Compound 10f) is a dual inhibitor of EGFR and BRAFV600E, with IC50 values of 61 nM and 43 nM, respectively. It halts the cell cycle, induces apoptosis in both early and late stages, and inhibits cancer cell growth in vitro, showing broad-spectrum anticancer activity.</p>
    Formula:C22H16N4OS
    Colore e forma:Solid
    Peso molecolare:384.45
  • Multi-kinase-IN-6


    Multi-kinase-IN-6 (compound 10e) is a multikinase inhibitor that effectively impedes the activity of TrkA, ALK2, c-KIT, EGFR, PIM1, CK2α, CHK1, and CDK2.
    Purezza:98%
    Colore e forma:Odour Solid
  • ML 2-23


    <p>ML 2-23 is a potent BCR-ABL degrader operating as a PROTAC, exhibiting selective proteasome-dependent degradation of BCR-ABL within leukemia cells [1].</p>
    Formula:C47H53BrCl2N10O7S
    Purezza:98%
    Colore e forma:Solid
    Peso molecolare:1052.86
  • FGFR-IN-19


    <p>Arg-IN-1 is a selective covalent inhibitor targeting Arginine (Arg), with IC50 values of 9.7 nM and 30.4 nM for FGFR2 and FGFR3, respectively. This compound is designed to potentially avoid the off-target toxicity of FGFR1/4 and overcome acquired resistance, offering potential in cancer therapies targeting FGFR.</p>
    Formula:C36H42N12O6
    Colore e forma:Solid
    Peso molecolare:738.33503
  • EGFR T790M/L858R-IN-2


    <p>EGFRT790M/L858R-IN-2: selective inhibitor, IC50: 3.5 nM (mutant), 1290 nM (WT); reduces p-EGFR/AKT/ERK1/2, triggers apoptosis, G1 arrest, anti-cancer.</p>
    Formula:C28H28FN7O
    Colore e forma:Solid
    Peso molecolare:497.57
  • 2-Keto Crizotinib

    CAS:
    2-Keto Crizotinib is an active lactam metabolite of crizotinib.
    Formula:C21H20Cl2FN5O2
    Purezza:98%
    Colore e forma:Solid
    Peso molecolare:464.32
  • Amuvatinib hydrochloride

    CAS:
    Amuvatinib HCl (MP470 HCl) is a multi-targeted oral tyrosine kinase inhibitor and hinders RAD51-mediated DNA repair, exhibiting anticancer properties.
    Formula:C23H22ClN5O3S
    Purezza:98%
    Colore e forma:Solid
    Peso molecolare:483.97
  • YH32367


    <p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>
    Colore e forma:Odour Liquid
  • VEGFR2/HDAC1-IN-1


    VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.
    Purezza:98%
    Colore e forma:Odour Solid